<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J. Neurol</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26705120</article-id><article-id pub-id-type="pmc">4826656</article-id><article-id pub-id-type="publisher-id">7963</article-id><article-id pub-id-type="doi">10.1007/s00415-015-7963-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurological Update</subject></subj-group></article-categories><title-group><article-title>Myasthenia gravis: a clinical-immunological update</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Binks</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vincent</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Palace</surname><given-names>Jacqueline</given-names></name><address><email>jacqueline.palace@ndcn.ox.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU UK </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>263</volume><fpage>826</fpage><lpage>834</lpage><history><date date-type="received"><day>6</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Myasthenia gravis (MG) is the archetypic disorder of both the neuromuscular junction and autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine receptors cause fatigable weakness of skeletal muscles. In the rest, a variable proportion possesses antibodies to muscle-specific tyrosine kinase while the remainder of seronegative MG is being explained through cell-based assays using a receptor-clustering technique and, to a lesser extent, proposed new antigenic targets. The incidence and prevalence of MG are increasing, particularly in the elderly. New treatments are being developed, and results from the randomised controlled trial of thymectomy in non-thymomatous MG, due for release in early 2016, will be of particular clinical value. To help navigate an evidence base of varying quality, practising clinicians may consult new MG guidelines in the fields of pregnancy, ocular and generalised MG (GMG). This review focuses on updates in epidemiology, immunology, therapeutic and clinical aspects of GMG in adults.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Myasthenia gravis</kwd><kwd>MuSK</kwd><kwd>LRP4</kwd><kwd>IgG4</kwd><kwd>Cell-based assays</kwd><kwd>Neuromuscular junction</kwd><kwd>Thymectomy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Myasthenia gravis (MG) represents the archetypic disorder of both the neuromuscular junction (NMJ) and autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine receptors (AChRs) cause fatigable weakness of skeletal muscles with an ocular onset in up to 85&#x000a0;% [<xref ref-type="bibr" rid="CR1">1</xref>]. A variable proportion of patients lacking AChR antibodies, termed seronegative MG (SNMG), possess antibodies to muscle-specific tyrosine kinase (MuSK) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and intriguingly, these antibodies are principally IgG4 [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. The remainder of SNMG is now rapidly being explained via cell-based assays (CBAs) using a receptor-clustering technique [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], and, to a lesser extent, proposed new antigenic targets [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>The incidence and prevalence of MG are increasing, particularly in older individuals [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. However, MG remains a rare disease and there are well-documented impediments to clinical trials including low participant recruitment [<xref ref-type="bibr" rid="CR12">12</xref>]. Indeed, the EPITOME trial [<xref ref-type="bibr" rid="CR13">13</xref>] in ocular MG (OMG) had to close recently due to failure to recruit adequate numbers [<xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, rituximab appears to show promise in MuSK MG [<xref ref-type="bibr" rid="CR15">15</xref>] and a much-anticipated randomised controlled trial (RCT) of thymectomy in non-thymomatous MG [<xref ref-type="bibr" rid="CR16">16</xref>] is due to report in early 2016. These results will be of great value since thymectomy has been offered for many years in this setting, without incontrovertible evidence of benefit compared to purely medical management [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Expert clinical guidelines have reviewed pregnancy in MG [<xref ref-type="bibr" rid="CR19">19</xref>], and management guidelines have been published for OMG [<xref ref-type="bibr" rid="CR20">20</xref>] and generalised MG (GMG) (with some comments on OMG) [<xref ref-type="bibr" rid="CR21">21</xref>]. This review will focus on GMG, as recent updates on congenital myasthenia [<xref ref-type="bibr" rid="CR22">22</xref>] and OMG [<xref ref-type="bibr" rid="CR23">23</xref>] have already been published. However, in addition to the epidemiology, immunology, therapeutics and clinical management of GMG, ongoing efforts to define the risk of generalisation (ROG) from ocular to generalised MG will be described.</p></sec><sec id="Sec2"><title>Epidemiology: the changing face of myasthenia gravis</title><p>Calculations of total MG incidence and prevalence, based on 55 studies spanning 1950&#x02013;2007, have yielded a pooled incidence rate (IR) of 5.3 per million person-years and a prevalence rate (PR) of 77.7 cases per million of the population [<xref ref-type="bibr" rid="CR10">10</xref>]. Marked heterogeneity and the varying quality of epidemiological studies, were, not surprisingly, notable factors influencing these estimations over so many years [<xref ref-type="bibr" rid="CR10">10</xref>]. Nevertheless, it is well recognised that MG prevalence has been rising since the middle of the last century [<xref ref-type="bibr" rid="CR24">24</xref>], with improved recognition and diagnosis, medical and intensive care advances and patient longevity all playing a role [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p>The yearly incidence has also risen in all studies performed more recently [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], due to a pronounced increase among older males as well as females [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. It remains appreciable even after adjustment for life expectancy [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>] and is not paralleled in younger females or children [<xref ref-type="bibr" rid="CR30">30</xref>]. Studies of late-onset MG (LOMG) are hampered by the lack of unanimously agreed age of onset, with suggested cut-off points ranging from 40 to 75&#x000a0;years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>] (see Box <xref rid="Tab1" ref-type="table">1</xref>). The different HLA haplotype association in LOMG patients has been recognised since the 1980s [<xref ref-type="bibr" rid="CR35">35</xref>], but the increase in incidence could also be related to environmental aspects [<xref ref-type="bibr" rid="CR36">36</xref>] and better case detection [<xref ref-type="bibr" rid="CR28">28</xref>].<table-wrap id="Tab1"><label>Box 1</label><caption><p>Features of LOMG in selected literature [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">Country</th><th align="left">LOMG prevalence</th><th align="left">Onset age defined as</th></tr></thead><tbody><tr><td align="left">Evoli et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">Italy</td><td align="left">20.5&#x000a0;% (172/837) of an MG clinic cohort</td><td char="." align="char">&#x0003e;60</td></tr><tr><td align="left">Poulas et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">Greece</td><td align="left" colspan="2">Point prevalence 175.37 per million population in &#x02265;70&#x000a0;s, the highest of all age groups studied (range 4.7&#x02013;175.37)</td></tr><tr><td align="left">Vincent et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">UK</td><td align="left">Incidence rising to 9.9/100,000 per year in males and 4.8/100,000 in females</td><td align="left">&#x02265;60</td></tr><tr><td align="left">Meriggioli et al. [<xref ref-type="bibr" rid="CR1">1</xref>]</td><td align="left">N/a</td><td align="left">N/a</td><td align="left">&#x02265;40</td></tr><tr><td align="left">Murai et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">Japan</td><td align="left">LOMG/EOMG&#x000a0;=&#x000a0;28.8&#x000a0;% of MG in 1987 vs. 41.7&#x000a0;% of MG in 2006 in a national epidemiological study</td><td align="left">&#x02265;50<sup>a</sup> (LOMG)<break/>&#x02265;65<sup>a</sup> (EOMG)</td></tr><tr><td align="left">&#x0017d;ivkovi&#x00107; et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">USA</td><td align="left">66&#x000a0;% (114/174) of an MG clinic cohort</td><td char="." align="char">&#x0003e;50</td></tr><tr><td align="left">Alkhawajah et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Canada</td><td align="left">&#x0003e;50&#x000a0;% MG, based on a prior regional epidemiological study [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="left">&#x02265;65</td></tr><tr><td align="left">De Meel et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">The Netherlands</td><td align="left">35&#x000a0;% (34/96) of a University hospital MG cohort</td><td align="left">&#x02265;50</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>This study sub-divided patients into LOMG defined as &#x02265;50 and elderly onset defined as &#x02265;65</p></table-wrap-foot></table-wrap></p><p>Described immunological changes that occur with ageing including diminished B and T cell repertoires and activation, but environmental factors are also implicated [<xref ref-type="bibr" rid="CR36">36</xref>]. Although some investigators have reported a higher rate of thymomas in LOMG [<xref ref-type="bibr" rid="CR28">28</xref>], thymic hyperplasia is less common in older individuals [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] and thymectomy unusual unless thymoma is present, limiting samples available for study [<xref ref-type="bibr" rid="CR1">1</xref>]. The advent of robotic and other minimally invasive operative techniques may alter this scenario, since data now suggest that the operation is safe in older individuals and potentially beneficial if hyperplasia is present [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Whether the surgical fitness of these elderly Japanese cohorts can be extrapolated to other elderly populations requires consideration.</p><p>Currently, a UK multicentre trial to define immunological, phenotypic and clinical features, including optimal treatment, of LOMG is recruiting and at the time of writing is at 41&#x000a0;% of target [<xref ref-type="bibr" rid="CR39">39</xref>]. This is important as, historically, there is evidence of misdiagnosis among older individuals, particularly with cerebrovascular disease [<xref ref-type="bibr" rid="CR26">26</xref>] and new diagnoses have been made in those as old as 98 [<xref ref-type="bibr" rid="CR40">40</xref>]. Older patients are less likely to enter complete stable remission [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and are more likely to suffer exacerbation with poorer outcomes, including death [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Their management is also challenging because they are more likely to have co-morbidities [<xref ref-type="bibr" rid="CR33">33</xref>] and are at higher risk of side-effects from acetylcholinesterase inhibition [<xref ref-type="bibr" rid="CR42">42</xref>] and steroids [<xref ref-type="bibr" rid="CR33">33</xref>].</p><sec id="Sec3"><title>The epidemiological story in MuSK</title><p>MuSK MG has a younger age of onset and female predominance [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. Initially, MuSK antibodies were reported to be prevalent in 70&#x000a0;% of &#x02018;seronegative&#x02019; sera [<xref ref-type="bibr" rid="CR2">2</xref>]. Subsequent cohorts, probably including patients with less severe disease, detected MuSK positivity less frequently in SNMG, but with wide variations [<xref ref-type="bibr" rid="CR48">48</xref>]. For example, 3.8&#x000a0;% of SNMG tested positive for MuSK in a Chinese cohort [<xref ref-type="bibr" rid="CR49">49</xref>] whereas in Italy the rate reached 47.4&#x000a0;% [<xref ref-type="bibr" rid="CR44">44</xref>]. Accordingly, incidence and prevalence rates in MuSK MG epidemiological studies have differed with higher rates in Greece [annual IR of 0.32 patients/million population per year and prevalence rates (PR) of 2.92 per million population] compared to The Netherlands (where these rates are 0.10 and 1.9, respectively) [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The variation in incidence in these studies and others [<xref ref-type="bibr" rid="CR48">48</xref>; A Vincent, unpublished observations] support an environmental factor, but since there is also an association with HLA DQ5 across Dutch, Italian and Turkish populations [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>], it suggests this acts on patients with a genetic predisposition.</p></sec></sec><sec id="Sec4"><title>Immunological advances: new techniques, an emerging pathogenic player and proposed new antigenic targets</title><sec id="Sec5"><title>Cell-based assays using clustered acetylcholine receptors</title><p>Traditionally, radioimmunoassays (RIA) (where the antigen is present in solution) are used for antibody ascertainment in MG. However, AChRs expressed on a mammalian cell line (human embryonic kidney cells, HEK) more closely mirror physiological conditions and increase sensitivity and specificity compared to solid phase assays for many antigenic targets [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. For MG, a clustered AChR cell-based assay (CBA) was established, in which the AChR subunits are expressed together with rapsyn, a post-synaptic protein crucial for AChR clustering at the NMJ. Using this method, AChR antibodies could be identified in 66&#x000a0;% of previously SNMG sera. These antibodies were primarily of the IgG1 sub-type and, in agreement with their pathogenic potential, could activate complement [<xref ref-type="bibr" rid="CR6">6</xref>] and transfer neuromuscular transmission defects to mice [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>50&#x000a0;% of previously seronegative OMG patients also had IgG1 clustered AChR antibodies [<xref ref-type="bibr" rid="CR7">7</xref>]. As in all similar studies, it is not always clear whether the cohorts used are representative of the spectrum of incident cases, but clustered CBA antibodies have been found helpful in the diagnosis of young or childhood MG with often mild or ocular disease, responding well to immunotherapies [<xref ref-type="bibr" rid="CR8">8</xref>]. The phenotype may become better defined as more laboratories adopt the clustered CBA [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p>The use of CBAs, with clustered antigens if appropriate, should improve both diagnosis and management of previously seronegative patients. Preliminary results from Oxford suggest 8&#x000a0;% of patients without MuSK or other antibodies bound detectably to MuSK expressed on HEK cells [<xref ref-type="bibr" rid="CR56">56</xref>]. An international study probing seronegative sera from 13 countries for binding to MuSK by CBA identified antibodies in 13&#x000a0;% of samples [<xref ref-type="bibr" rid="CR58">58</xref>], but many of the antibodies detected were predominantly of the IgM type, which is of unknown relevance.</p></sec><sec id="Sec6"><title>IgG4: a new pathogenic player</title><p>MuSK is a post-synaptic protein which is critical for the development and maintenance of the NMJ [reviewed in <xref ref-type="bibr" rid="CR59">59</xref>]. Agrin is released from the presynaptic nerve terminal and binds to low-density lipoprotein receptor 4 (Lrp4), which in turn binds to and activates MuSK. This leads to MuSK phosphorylation, ultimately resulting in the clustering of rapsyn and AChR on top of post-synaptic folds; this AChR clustering is essential for efficient transmission at the NMJ [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p><p>MuSK antibodies are mainly IgG4 [<xref ref-type="bibr" rid="CR3">3</xref>], in contrast to the IgG1 and IgG3 dominance of AChR antibodies. AChR antibodies principally act through complement activation, and by cross-linking and internalisation of receptors [<xref ref-type="bibr" rid="CR1">1</xref>], both of which require antibody divalency. However, MuSK IgG4 antibodies are thought to be single chain rather than divalent, and do not activate complement or cause cross-linking of the MuSK molecules [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Nevertheless, the pathogenicity of MuSK IgG4 antibodies has been demonstrated and overall the titres in a patient relate well to disease severity with reductions on remission [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Injection of purified IgG4 into experimental animals leads to defects in neuromuscular transmission with AChR loss [<xref ref-type="bibr" rid="CR65">65</xref>] as does injection of purified IgG [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p>MuSK IgG4 antibodies act through direct inhibition of MuSK-Lrp4 binding, without receptor dimerization or endocytosis, whereas this was not found with the remaining IgG1&#x02013;3 antibodies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. However, both these IgG1&#x02013;3 antibodies and IgG4 antibodies could disperse AChR clusters in a mouse muscle cell line [<xref ref-type="bibr" rid="CR4">4</xref>], implying that IgG1&#x02013;3 could play a role in the disease; it is possible that by binding divalently, and activating phosphorylation, they cause desensitisation of MuSK leading to loss of function by that mechanism.</p><p>IgG4 antibodies were previously little known in autoimmune disease and thought to occur as a benign phenomenon in conjunction with resolution of allergic reactions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. However, they are recognised in other diseases, such as forms of pemphigus, and represent a field of growing interest [<xref ref-type="bibr" rid="CR62">62</xref>].</p></sec><sec id="Sec7"><title>Continuing the search for new epitopes</title><p>Although antibodies detectable via clustered CBAs are likely to be diagnostic in the majority of currently &#x02018;seronegative&#x02019; patients, the hunt continues for antibodies to other elements of the NMJ which may be disease causative in smaller sub-sets of patients.</p><sec id="Sec8"><title>LRP4</title><p>As the partner of MuSK, Lrp4 is similarly essential in development and for normal function of the adult NMJ, where it performs both anterograde and retrograde signalling roles [<xref ref-type="bibr" rid="CR67">67</xref>]. These roles highlighted it as a putative antigen of interest, and LRP4 antibodies have been reported in Japanese [<xref ref-type="bibr" rid="CR68">68</xref>] and European [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>] patients. The antibodies were of the complement-activating IgG1 type [<xref ref-type="bibr" rid="CR68">68</xref>] and impeded agrin-induced clustering of AChRs [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. These antibodies have now been examined by a number of groups and overall their presence in seronegative sera has varied widely (Table&#x000a0;<xref rid="Tab2" ref-type="table">1</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;1</label><caption><p>Prevalence of LRP4 antibodies in studies of seronegative MG [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Investigators</th><th align="left">Experimental method</th><th align="left">Prevalence in SNMG</th><th align="left">Definition of SNMG</th><th align="left">Double positives</th></tr></thead><tbody><tr><td align="left">Higuchi et al. [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">Luciferase-reporter immunoprecipitation</td><td align="left">3&#x000a0;% (9/300)</td><td align="left">AChR &#x02212;ve</td><td align="left">3 of the 9 LRP4 +ve samples were also MuSK +ve</td></tr><tr><td align="left">Pevzner et al. [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">CBA</td><td align="left">54&#x000a0;% (7/13)</td><td align="left">AChR and MuSK &#x02212;ve</td><td align="left">A control MuSK sample was also LRP4 +ve</td></tr><tr><td align="left">Zhang et al. [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">ELISA</td><td align="left">9.2&#x000a0;% (11/120)</td><td align="left">AChR and MuSK &#x02212;ve</td><td align="left">1 of 36 MuSK samples tested was also LRP4 +ve</td></tr><tr><td align="left">Zisimopoulou et al. [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">CBA</td><td align="left">18.7&#x000a0;% (119/635)</td><td align="left">AChR and MuSK &#x02212;ve</td><td align="left">8/107 AChR +ve and 10/67 MuSK +ve samples also LRP4 +ve</td></tr></tbody></table></table-wrap></p><p>These discrepant results are likely to emanate at least in part from the different assays used by separate research groups [<xref ref-type="bibr" rid="CR9">9</xref>]. The potential of certain commercial secondary antibodies to detect non-specific binding of IgM antibodies to MuSK has been noted (S Huda, unpublished results). In addition to clarifying the specificities and sensitivities of these different LRP4 antibody assays, the relevance of the antibodies when found in association with other pathogenic myasthenia antibodies (see Table&#x000a0;<xref rid="Tab2" ref-type="table">1</xref>) needs exploration. Further definition of the clinical phenotype of LRP4 disease is also required although present information suggests this is a predominantly female cohort with mild symptoms, similar to AChR-antibody-positive patients [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>].</p></sec><sec id="Sec9"><title>Agrin and ColQ</title><p>Antibodies to agrin have recently been identified in a small number of &#x02018;triple negative&#x02019; MG sera (samples negative for AChR, MuSK and LRP4 antibodies) at proportions ranging from 15 to 50&#x000a0;% [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. These antibodies have sometimes been at low titres [<xref ref-type="bibr" rid="CR72">72</xref>] and can be found with [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR72">72</xref>] or only with AChR or MuSK antibodies [<xref ref-type="bibr" rid="CR73">73</xref>]. This suggests technical difficulties and methodologies need to improve before the significance of agrin antibodies can be evaluated.</p><p>ColQ tethers MuSK within the synapse [<xref ref-type="bibr" rid="CR74">74</xref>] and is thought to interact also with MuSK. ColQ antibodies were reported in 3&#x02013;4&#x000a0;% of all MG patient sera tested and 1.2&#x02013;5.5&#x000a0;% of the AChR/MuSK/LRP4 negative samples [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR75">75</xref>] but again the specificities are unclear and further work is required to delineate their role [<xref ref-type="bibr" rid="CR75">75</xref>].</p></sec></sec></sec><sec id="Sec10"><title>A link with antibody-mediated demyelinating disorders?</title><p>The co-occurrence of MG and demyelinating disorders happens more than would be expected by chance [<xref ref-type="bibr" rid="CR76">76</xref>]. Recently, a cohort of 16 patients with neuromyelitis optica (NMO) and MG was described. In such cases, the MG tended to be mild and 90&#x000a0;% presented with a prior history of NMO; however, Aquaporin-4 (AQP4) antibodies could pre-date clinically evident NMO by up to 16&#x000a0;years [<xref ref-type="bibr" rid="CR76">76</xref>]. Of note, in other case series of MG presenting with demyelinating disorders described as MS or ADEM, AQP4 testing was not reported; some of these may have represented NMO [<xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR79">79</xref>] and in at least one case this was subsequently confirmed [<xref ref-type="bibr" rid="CR78">78</xref>]. LRP4 antibodies have also been described in NMO patients, albeit without a known diagnosis of MG, but not other neurological disorders [<xref ref-type="bibr" rid="CR70">70</xref>]. Why these two diseases should occur in this order, with AQP4 antibodies rising over time, is not understood, although it is speculated that thymectomy may play a triggering role. Clinicians should at least be vigilant to the possible co-existence of NMO with MG, particularly in young patients with AChR-antibody-positive disease and should test for AQP4 antibodies in MG patients who develop MS or other demyelinating disorders [<xref ref-type="bibr" rid="CR76">76</xref>].</p></sec><sec id="Sec11"><title>Risk of generalisation from OMG: setbacks and progress</title><p>The debate over the risk of generalisation from ocular to generalised MG continues. Retrospective patient data indicate that most OMG patients who develop GMG do so in the first 2&#x000a0;years [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>]. However, unanimity has not been reached on other risk factors, or on whether early intervention with immunosuppressants, particularly corticosteroids, can delay or prevent the onset of GMG [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. This is of growing relevance in the era of expanding therapeutic and surgical options, and to avoid exposing patients to unnecessary adverse effects of immunotherapies.</p><p>Several retrospective cohorts have reported lower rates of generalisation in patients treated with corticosteroids compared to those treated with acetylcholinesterase inhibitors alone [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>], but solid conclusions cannot be drawn from these non-randomised studies where confounding factors such as duration of OMG, serological status and differing steroid regimes are present. In some cases, patients received lengthy courses of steroids (up to 92&#x000a0;months) or were maintained on low-dose steroid regimes, either of which could have masked the development of GMG [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Moreover, Grob&#x02019;s survey of nearly 2000 patients between 1940 and 2000 found stable rates of generalisation from OMG [<xref ref-type="bibr" rid="CR85">85</xref>], which might seem to contradict a disease-modifying effect of corticosteroid treatment.</p><p>The EPITOME trial [<xref ref-type="bibr" rid="CR13">13</xref>], which was due to address these issues, would therefore have been of great clinical utility but unfortunately its closure was recently announced due to poor recruitment [<xref ref-type="bibr" rid="CR14">14</xref>]. A UK initiative to develop a prognostic &#x02018;ROG&#x02019; score is still in progress and reported preliminary results at the 2015 Association of British Neurologists conference. Using available case notes, investigators identified the three positive factors most predictive of secondary generalisation as being thymic hyperplasia, seropositivity and co-morbidity (including but not limited to other autoimmune disorders) [<xref ref-type="bibr" rid="CR86">86</xref>]. Such a model should now be prospectively validated and could help identify high-risk patients for whom early immunosuppression would be beneficial.</p><sec id="Sec12"><title>The therapeutic landscape</title><p>Pyridostigmine and corticosteroids retain a central role in the management of GMG [<xref ref-type="bibr" rid="CR87">87</xref>]. Use of azathioprine as a steroid-sparing agent is supported by an RCT [<xref ref-type="bibr" rid="CR88">88</xref>] but limited high quality evidence underlies many other immunosuppressants [<xref ref-type="bibr" rid="CR87">87</xref>]. However, recently, a single-blinded trial proposed methotrexate as an alternative to azathioprine [<xref ref-type="bibr" rid="CR89">89</xref>]. While this trial was devised to validate methotrexate in a resource-limited setting, it may have applicability for azathioprine-intolerant individuals.</p><p>MuSK MG patients have traditionally represented a clinical challenge as they exhibit poor response to acetylcholinesterase inhibitors [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Rituximab, an anti-CD20 monoclonal antibody, is emerging as a potential option in this cohort [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR91">91</xref>&#x02013;<xref ref-type="bibr" rid="CR93">93</xref>]. Following rituximab treatment, some patients even revert to a seronegative status [<xref ref-type="bibr" rid="CR15">15</xref>]. Of particular interest, specific monitoring of IgG sub-classes in five clinically improved rituximab-treated MuSK MG individuals demonstrated significantly reduced IgG4 titres in all five. On the other hand, both clinical and serologic impact was much less favourable in AChR antibody patients treated in the same study [<xref ref-type="bibr" rid="CR92">92</xref>]. Indeed, rituximab appears to be a useful treatment in other IgG4-related diseases and to act by eliminating a population of B- or plasma cells responsible for the production of IgG4 antibodies [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Rituximab&#x02019;s effect on T cell response may also be relevant, and an increase in T-regulatory cells has been observed post-rituximab administration in a refractory MuSK, but not AChR-positive, patient [<xref ref-type="bibr" rid="CR94">94</xref>]. Further work is required to determine the optimal timing and administration schedule of rituximab in MG [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p>Another monoclonal antibody being considered for MG is eculizumab, which targets the C5 protein of the complement cascade, and so might protect the NMJ from complement-mediated damage. In a small phase II trial, there was significant change on the quantitative myasthenia gravis score (QMGS) with eculizumab compared to placebo [<xref ref-type="bibr" rid="CR95">95</xref>]. A phase III trial is now in progress, aiming to enrol 92 patients [<xref ref-type="bibr" rid="CR96">96</xref>]. The weekly dosing schedule and high cost of this medication may limit its use.</p><p>Early stage agents in development include EN101/Monarsen, an antisense oligonucleotide to mRNA of a splicing variant of acetylcholinesterase which is elevated in mice with experimental autoimmune MG and in patients. It is currently unclear whether clinical effect is due to inhibition of the splicing variant, producing symptomatic relief, or anti-inflammatory and immunomodulatory actions via the NF-&#x003ba;B pathway [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Another drug in phase II studies is Tirasemtiv, which enhances skeletal muscle&#x02019;s response to calcium and may be of benefit in combination with acetylcholinesterase inhibitors [<xref ref-type="bibr" rid="CR99">99</xref>].</p></sec><sec id="Sec13"><title>Emergency treatments</title><p>A RCT of plasma exchange (PLEX) compared to IVIg in myasthenic crisis found equivalence between the two treatments [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. After 2&#x000a0;weeks, similar numbers improved in both groups, as measured on the QMGS. Although more patients (17.5&#x000a0;%) had worse 2-week QMGS scores in the IVIg group compared to those receiving PLEX (2&#x000a0;%), this was non-significant [<xref ref-type="bibr" rid="CR100">100</xref>]. Recent hospital data show a trend to declining use of PLEX, which may be prompted by the invasive nature of this treatment modality [<xref ref-type="bibr" rid="CR41">41</xref>] and its lack of availability in many centres. Nevertheless, it is important to note that in several cohorts, MuSK MG patients appear to respond less well to IVIg than PLEX [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR90">90</xref>].</p></sec></sec><sec id="Sec14"><title>Thymectomy: towards a definitive answer</title><p>The announcement of the results of the MGTX RCT of thymectomy vs. medical treatment in AChR-antibody-positive GMG patients will take place in Oxford in early 2016 and is likely to be a milestone event for myasthenic treatment. The protocol of this multicentre (&#x0003e;40 centre) trial has previously been published and is a single-blind, double armed trial evaluating trans-sternal thymectomy versus no operation in patients on prednisolone [<xref ref-type="bibr" rid="CR16">16</xref>]. Some initial reports of thymic pathology in trial participants have been published and revealed 25&#x02013;40&#x000a0;% thymic hyperplasia depending on the immunostaining method used, and parenchymal changes comparable to the non-MG population [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p>Where a thymoma is present, thymectomy is indicated to treat the tumour but not the myasthenia; however, frail and elderly patients are sometimes treated medically. On the other hand, in MuSK MG patients, thymic pathology is relatively rare [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>] although cannot be precluded [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Few MuSK patients appear to improve following the procedure [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] or, similar to AChR patients, are maintained on corticosteroids [<xref ref-type="bibr" rid="CR47">47</xref>] which cloud the interpretation of any operative effects. Until MGTX reports, the situation remains difficult with no high quality evidence available to support decision making [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The American Academy of Neurology (AAN) has developed guidelines to assist in this scenario [<xref ref-type="bibr" rid="CR17">17</xref>], advising thymectomy be viewed as an option to improve clinical status and remission rates.</p><p>Another conundrum is whether a trans-sternal, minimally invasive or robotic approach offers best results. The MGTX will not answer this question, but it is sensible first to establish clinical benefit of any operative intervention prior to probing competing techniques [<xref ref-type="bibr" rid="CR106">106</xref>]. Comparable results of around 28&#x02013;34&#x000a0;% complete stable remission (CSR) or CSR and pharmacological remission (PR) have been achieved in single-centre, non-randomised case series from different hospitals [<xref ref-type="bibr" rid="CR106">106</xref>&#x02013;<xref ref-type="bibr" rid="CR110">110</xref>]. One single-centre review of patient records displayed superior rates of complete remission with robotic (39.25&#x000a0;%) compared to thoracoscopic surgery (20.3&#x000a0;%), but the dates of all thoracoscopic surgeries predated robotic procedures, introducing the possibility of confounding historical factors [<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec><sec id="Sec15"><title>New best practice guidelines</title><p>New best practice guidelines have been released in the past 2&#x000a0;years which address ocular and generalised MG as well as pregnancy in MG [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Key points are summarised in Box <xref rid="Tab3" ref-type="table">2</xref>. An important message for expectant mothers is that birth plans should aim for a hospital delivery as babies are at risk of transient neonatal MG irrespective of the mother&#x02019;s disease status. Therefore, home births and midwife-led units are not advised [<xref ref-type="bibr" rid="CR21">21</xref>].<table-wrap id="Tab3"><label>Box 2</label><caption><p>Take-home messages from recent best practice guidelines [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group</td></tr><tr><td align="left">&#x000a0;Norwood et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left">&#x000a0;&#x000a0;Key points</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Importance of pre-conception planning</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Pyridostigmine, prednisolone (at lowest dose) and azathioprine may be used</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Mycophenolate and methotrexate are teratogenic and contra-indicated in pregnancy</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Monitoring, e.g. gestational diabetes in women on steroids</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Aim for a vaginal delivery, but supported by multidisciplinary expertise</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Babies need post-delivery monitoring due to risk of transient neonatal MG</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Home births and midwife-led units are therefore not recommended</td></tr><tr><td align="left">EFNS/ENS Guidelines for the treatment of ocular myasthenia</td></tr><tr><td align="left">&#x000a0;Kerty et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left">&#x000a0;&#x000a0;Key points</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Start with pyridostigmine treatment</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Add in steroids if symptoms not controlled (will be required in most cases)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Next line is azathioprine</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Some reports suggest thymectomy may reduce risk of secondary generalisation</td></tr><tr><td align="left">Myasthenia: association of British Neurologists&#x02019; management guidelines</td></tr><tr><td align="left">&#x000a0;Sussman et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">&#x000a0;&#x000a0;Key points</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;First line tests: AChR antibodies, thyroid function tests, thymus scan</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Second line tests: MuSK antibodies, neurophysiology, MRI brain</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Provides escalation protocols for pyridostigmine and steroids in both OMG and GMG, including the option of every other day dosing</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Advises bone protection</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Azathioprine is first line in patients who do not achieve remission on prednisolone or who require long-term steroid doses in excess of 15-20&#x000a0;mg on alternate days</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;IVIg or PLEX may be given in crisis (PLEX if specific risk factors)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Thymectomy should be performed in a specialist centre with an experienced surgeon</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Thymectomy in non-thymomatous MG is a &#x02018;reasonable treatment option&#x02019; for patients &#x0003c;45 who are AChR antibody positive</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec16"><title>Conclusions</title><p>This paper has reviewed a number of evolving areas in GMG. In particular, patient diagnosis and management will improve as the pool of &#x02018;seronegative&#x02019; MG decreases. However, care should be taken to establish the pathogenicity of newly identified antibodies. It is likely the field of IgG4-mediated disease will continue to gain scientific momentum.</p><p>More work is required to understand the phenomenon of increasing incidence of LOMG, with elderly patients posing a diagnostic and therapeutic challenge. Within the next 12&#x000a0;months, the results of the MGTX trial may answer one of the longest-standing questions in MG, namely, the role of thymectomy in non-thymomatous disease.</p></sec></body><back><notes notes-type="conflict-interest"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflicts of interest</title><p>Angela Vincent and University of Oxford holds a patent for MuSK antibody assays, licensed to Athena Diagnostics, and receives royalties from this.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meriggioli</surname><given-names>MN</given-names></name><name><surname>Sanders</surname><given-names>DB</given-names></name></person-group><article-title>Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>5</issue><fpage>475</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70063-8</pub-id><pub-id pub-id-type="pmid">19375665</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>W</given-names></name><name><surname>McConville</surname><given-names>J</given-names></name><name><surname>Helms</surname><given-names>S</given-names></name><etal/></person-group><article-title>Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><issue>3</issue><fpage>365</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/85520</pub-id><pub-id pub-id-type="pmid">11231638</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConville</surname><given-names>J</given-names></name><name><surname>Farrugia</surname><given-names>ME</given-names></name><name><surname>Beeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Detection and characterization of MuSK antibodies in seronegative myasthenia gravis</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><issue>4</issue><fpage>580</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1002/ana.20061</pub-id><pub-id pub-id-type="pmid">15048899</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koneczny</surname><given-names>I</given-names></name><name><surname>Cossins</surname><given-names>J</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name><etal/></person-group><article-title>MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e80695</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080695</pub-id><pub-id pub-id-type="pmid">24244707</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijbers</surname><given-names>MG</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Klooster</surname><given-names>R</given-names></name><etal/></person-group><article-title>MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><issue>51</issue><fpage>20783</fpage><lpage>20788</lpage><pub-id pub-id-type="doi">10.1073/pnas.1313944110</pub-id><pub-id pub-id-type="pmid">24297891</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>MI</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Viegas</surname><given-names>S</given-names></name><etal/></person-group><article-title>IgG1 antibodies to acetylcholine receptors in &#x02018;seronegative&#x02019; myasthenia gravis</article-title><source>Brain</source><year>2008</year><volume>131</volume><issue>Pt 7</issue><fpage>1940</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1093/brain/awn092</pub-id><pub-id pub-id-type="pmid">18515870</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Viegas</surname><given-names>S</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><issue>8</issue><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2012.437</pub-id><pub-id pub-id-type="pmid">22689047</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez Cruz</surname><given-names>PM</given-names></name><name><surname>Al-Hajjar</surname><given-names>M</given-names></name><name><surname>Huda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis</article-title><source>JAMA Neurol</source><year>2015</year><volume>72</volume><issue>6</issue><fpage>642</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2015.0203</pub-id><pub-id pub-id-type="pmid">25894002</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cossins</surname><given-names>J</given-names></name><name><surname>Belaya</surname><given-names>K</given-names></name><name><surname>Zoltowska</surname><given-names>K</given-names></name><etal/></person-group><article-title>The search for new antigenic targets in myasthenia gravis</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1275</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06833.x</pub-id><pub-id pub-id-type="pmid">23278587</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>AS</given-names></name><name><surname>Cardwell</surname><given-names>CR</given-names></name><name><surname>McCarron</surname><given-names>PO</given-names></name><etal/></person-group><article-title>A systematic review of population based epidemiological studies in myasthenia gravis</article-title><source>BMC Neurol</source><year>2010</year><volume>18</volume><issue>10</issue><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-10-46</pub-id><pub-id pub-id-type="pmid">20565885</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakzad</surname><given-names>Z</given-names></name><name><surname>Aziz</surname><given-names>T</given-names></name><name><surname>Oger</surname><given-names>J</given-names></name></person-group><article-title>Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada</article-title><source>Neurology</source><year>2011</year><volume>76</volume><issue>17</issue><fpage>1526</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318217e735</pub-id><pub-id pub-id-type="pmid">21519005</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benatar</surname><given-names>M</given-names></name><name><surname>Sanders</surname><given-names>DB</given-names></name><name><surname>Burns</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Recommendations for myasthenia gravis clinical trials</article-title><source>Muscle Nerve</source><year>2012</year><volume>45</volume><issue>6</issue><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/mus.23330</pub-id><pub-id pub-id-type="pmid">22581550</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benatar</surname><given-names>M</given-names></name><name><surname>Sanders</surname><given-names>DB</given-names></name><name><surname>Wolfe</surname><given-names>GI</given-names></name><etal/></person-group><article-title>Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1275</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06780.x</pub-id><pub-id pub-id-type="pmid">23278573</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Clinical trials.gov. Efficacy of prednisone in the treatment of ocular myasthenia (EPITOME). ClinicalTrials.gov identifier NCT00995722 [on-line]. Web-page last updated 2015 Jan 6. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00995722?term=EPITOME&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/NCT00995722?term=EPITOME&#x00026;rank=1</ext-link>. Accessed 13 Aug 2015</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keung</surname><given-names>B</given-names></name><name><surname>Robeson</surname><given-names>KR</given-names></name><name><surname>DiCapua</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>12</issue><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-303664</pub-id><pub-id pub-id-type="pmid">23761915</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>GI</given-names></name><name><surname>Kaminski</surname><given-names>HJ</given-names></name><name><surname>Jaretzki</surname><given-names>A</given-names></name><etal/></person-group><article-title>Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy</article-title><source>Ann N Y Acad Sci</source><year>2003</year><volume>998</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1196/annals.1254.061</pub-id><pub-id pub-id-type="pmid">14592916</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gronseth</surname><given-names>GS</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name></person-group><article-title>Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology</article-title><source>Neurology</source><year>2000</year><volume>55</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.1.7</pub-id><pub-id pub-id-type="pmid">10891896</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Cea G, Benatar M, Verdugo RJ et al (2013) Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10:CD008111</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norwood</surname><given-names>F</given-names></name><name><surname>Dhanjal</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><etal/></person-group><article-title>Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2014</year><volume>85</volume><issue>5</issue><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2013-305572</pub-id><pub-id pub-id-type="pmid">23757420</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerty</surname><given-names>E</given-names></name><name><surname>Elsais</surname><given-names>A</given-names></name><name><surname>Argov</surname><given-names>Z</given-names></name><etal/></person-group><article-title>EFNS/ENS Guidelines for the treatment of ocular myasthenia</article-title><source>Eur J Neurol</source><year>2014</year><volume>21</volume><issue>5</issue><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1111/ene.12359</pub-id><pub-id pub-id-type="pmid">24471489</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sussman</surname><given-names>J</given-names></name><name><surname>Farrugia</surname><given-names>ME</given-names></name><name><surname>Maddison</surname><given-names>P</given-names></name><etal/></person-group><article-title>Myasthenia gravis: association of British Neurologists&#x02019; management guidelines</article-title><source>Pract Neurol</source><year>2015</year><volume>15</volume><issue>3</issue><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1136/practneurol-2015-001126</pub-id><pub-id pub-id-type="pmid">25977271</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>PMR</given-names></name><name><surname>Palace</surname><given-names>J</given-names></name><name><surname>Beeson</surname><given-names>D</given-names></name></person-group><article-title>Inherited disorders of the neuromuscular junction: an update</article-title><source>J Neurol.</source><year>2014</year><volume>261</volume><issue>11</issue><fpage>2234</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.1007/s00415-014-7520-7</pub-id><pub-id pub-id-type="pmid">25305004</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Huda</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ocular myasthenia gravis: controversies and updates</article-title><source>Curr Neurol Neurosci Rep</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>421</fpage><pub-id pub-id-type="doi">10.1007/s11910-013-0421-9</pub-id><pub-id pub-id-type="pmid">24272275</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>LH</given-names></name><name><surname>Torner</surname><given-names>JC</given-names></name></person-group><article-title>Epidemiologic evidence for a changing natural history of myasthenia gravis</article-title><source>Neurology</source><year>1996</year><volume>47</volume><issue>5</issue><fpage>1233</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.5.1233</pub-id><pub-id pub-id-type="pmid">8909435</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulas</surname><given-names>K</given-names></name><name><surname>Tisbri</surname><given-names>E</given-names></name><name><surname>Kokla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epidemiology of seropositive myasthenia gravis in Greece</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>71</volume><issue>3</issue><fpage>352</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1136/jnnp.71.3.352</pub-id><pub-id pub-id-type="pmid">11511710</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Clover</surname><given-names>L</given-names></name><name><surname>Buckley</surname><given-names>C</given-names></name><etal/></person-group><article-title>Evidence of underdiagnosis of myasthenia gravis in older people</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><issue>8</issue><fpage>1105</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.8.1105</pub-id><pub-id pub-id-type="pmid">12876244</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>N</given-names></name><name><surname>Nakane</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2009</year><volume>80</volume><issue>10</issue><fpage>1168</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2008.152637</pub-id><pub-id pub-id-type="pmid">19762910</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characteristics of myasthenia according to onset-age: Japanese nationwide survey</article-title><source>J Neurol Sci</source><year>2011</year><volume>305</volume><issue>1&#x02013;2</issue><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2011.03.004</pub-id><pub-id pub-id-type="pmid">21440910</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Somnier</surname><given-names>FE</given-names></name></person-group><article-title>Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>6</issue><fpage>928</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000176067.32186.a3</pub-id><pub-id pub-id-type="pmid">16186537</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parr</surname><given-names>JR</given-names></name><name><surname>Andrew</surname><given-names>MJ</given-names></name><name><surname>Finnis</surname><given-names>M</given-names></name><etal/></person-group><article-title>How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia</article-title><source>Arch Dis Child</source><year>2014</year><volume>99</volume><issue>6</issue><fpage>539</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2013-304788</pub-id><pub-id pub-id-type="pmid">24500997</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhawajah</surname><given-names>N</given-names></name><name><surname>Oger</surname><given-names>J</given-names></name></person-group><article-title>Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing</article-title><source>Muscle Nerve</source><year>2013</year><volume>48</volume><issue>5</issue><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1002/mus.23964</pub-id><pub-id pub-id-type="pmid">23893883</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Meel</surname><given-names>RH</given-names></name><name><surname>Lipka</surname><given-names>AF</given-names></name><name><surname>van Zwet</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Prognostic factors for exacerbations and emergency treatments in myasthenia gravis</article-title><source>J Neuroimmunol</source><year>2015</year><volume>15</volume><issue>282</issue><fpage>123</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2015.03.018</pub-id><pub-id pub-id-type="pmid">25903739</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evoli</surname><given-names>A</given-names></name><name><surname>Batocchi</surname><given-names>AP</given-names></name><name><surname>Minisci</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical characteristics and prognosis of myasthenia gravis in older people</article-title><source>J Am Geriatr Soc</source><year>2000</year><volume>48</volume><issue>11</issue><fpage>1442</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2000.tb02635.x</pub-id><pub-id pub-id-type="pmid">11083321</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0017d;ivkovi&#x00107;</surname><given-names>SA</given-names></name><name><surname>Clemens</surname><given-names>PR</given-names></name><name><surname>Lacomis</surname><given-names>D</given-names></name></person-group><article-title>Characteristics of late-onset myasthenia gravis</article-title><source>J Neurol</source><year>2012</year><volume>259</volume><issue>10</issue><fpage>2167</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1007/s00415-012-6478-6</pub-id><pub-id pub-id-type="pmid">22476514</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>DA</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Newsom-Davis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis</article-title><source>Brain</source><year>1980</year><volume>103</volume><issue>3</issue><fpage>579</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1093/brain/103.3.579</pub-id><pub-id pub-id-type="pmid">6968236</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>PJ</given-names></name><name><surname>Dorshkind</surname><given-names>K</given-names></name></person-group><article-title>Age-related changes in lymphocyte development and function</article-title><source>Nat Immunol</source><year>2004</year><volume>5</volume><issue>2</issue><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1038/ni1033</pub-id><pub-id pub-id-type="pmid">14749784</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzawa</surname><given-names>A</given-names></name><name><surname>Kawaguchi</surname><given-names>N</given-names></name><name><surname>Kanai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis</article-title><source>J Neurol</source><year>2015</year><volume>262</volume><issue>4</issue><fpage>1019</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1007/s00415-015-7673-z</pub-id><pub-id pub-id-type="pmid">25683765</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchida</surname><given-names>M</given-names></name><name><surname>Yamoto</surname><given-names>Y</given-names></name><name><surname>Souma</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis</article-title><source>Ann Thorac Surg</source><year>1999</year><volume>67</volume><issue>6</issue><fpage>1563</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(99)00167-8</pub-id><pub-id pub-id-type="pmid">10391255</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">UK clinical research network study portfolio. A prospective study of late-onset myasthenia gravis. UKCRN 13582 [on-line]. <ext-link ext-link-type="uri" xlink:href="http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13582">http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13582</ext-link>. Accessed 13 Aug 2015</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>LH</given-names></name><name><surname>Juel</surname><given-names>VC</given-names></name></person-group><article-title>Myasthenia gravis in the tenth decade</article-title><source>Muscle Nerve</source><year>1999</year><volume>22</volume><issue>9</issue><fpage>1297</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(199909)22:9&#x0003c;1297::AID-MUS22&#x0003e;3.0.CO;2-C</pub-id><pub-id pub-id-type="pmid">10454731</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshekhlee</surname><given-names>A</given-names></name><name><surname>Miles</surname><given-names>JD</given-names></name><name><surname>Katirji</surname><given-names>B</given-names></name><etal/></person-group><article-title>Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals</article-title><source>Neurology</source><year>2009</year><volume>72</volume><issue>18</issue><fpage>1548</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181a41211</pub-id><pub-id pub-id-type="pmid">19414721</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punga</surname><given-names>AR</given-names></name><name><surname>Sawada</surname><given-names>M</given-names></name><name><surname>Stalberg</surname><given-names>EV</given-names></name></person-group><article-title>Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis</article-title><source>Muscle Nerve</source><year>2008</year><volume>37</volume><issue>3</issue><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1002/mus.20935</pub-id><pub-id pub-id-type="pmid">18069667</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>DB</given-names></name><name><surname>El-Salem</surname><given-names>K</given-names></name><name><surname>Massey</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Clinical aspects of MuSK antibody positive seronegative MG</article-title><source>Neurology</source><year>2003</year><volume>60</volume><issue>12</issue><fpage>1978</fpage><lpage>1980</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000065882.63904.53</pub-id><pub-id pub-id-type="pmid">12821744</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evoli</surname><given-names>A</given-names></name><name><surname>Tonali</surname><given-names>PA</given-names></name><name><surname>Padua</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis</article-title><source>Brain</source><year>2003</year><volume>126</volume><issue>Pt 10</issue><fpage>2304</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1093/brain/awg223</pub-id><pub-id pub-id-type="pmid">12821509</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guptill</surname><given-names>JT</given-names></name><name><surname>Sanders</surname><given-names>DB</given-names></name><name><surname>Evoli</surname><given-names>A</given-names></name></person-group><article-title>Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts</article-title><source>Muscle Nerve</source><year>2011</year><volume>44</volume><issue>1</issue><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/mus.22006</pub-id><pub-id pub-id-type="pmid">21674519</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavrnic</surname><given-names>D</given-names></name><name><surname>Losen</surname><given-names>M</given-names></name><name><surname>Vujic</surname><given-names>A</given-names></name><etal/></person-group><article-title>The features of myasthenia gravis with autoantibodies to MuSK</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><issue>8</issue><fpage>1099</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2004.052415</pub-id><pub-id pub-id-type="pmid">16024887</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Pasnoor M, Wolfe GI, Nations S et al</collab></person-group><article-title>Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience</article-title><source>Muscle Nerve</source><year>2010</year><volume>41</volume><issue>3</issue><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1002/mus.21533</pub-id><pub-id pub-id-type="pmid">19882635</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name></person-group><article-title>Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis</article-title><source>Curr Opin Neurol</source><year>2005</year><volume>18</volume><issue>5</issue><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1097/01.wco.0000180660.57801.3f</pub-id><pub-id pub-id-type="pmid">16155434</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Chiu</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese</article-title><source>Neurology</source><year>2004</year><volume>62</volume><issue>11</issue><fpage>2131</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000128042.28877.C3</pub-id><pub-id pub-id-type="pmid">15184635</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsiamalos</surname><given-names>P</given-names></name><name><surname>Kordas</surname><given-names>G</given-names></name><name><surname>Kokla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><issue>8</issue><fpage>925</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02624.x</pub-id><pub-id pub-id-type="pmid">19374661</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niks</surname><given-names>EH</given-names></name><name><surname>Kuks</surname><given-names>JB</given-names></name><name><surname>Verschuuren</surname><given-names>JJ</given-names></name></person-group><article-title>Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><issue>4</issue><fpage>417</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2006.102517</pub-id><pub-id pub-id-type="pmid">17056627</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niks</surname><given-names>EH</given-names></name><name><surname>Kuks</surname><given-names>JB</given-names></name><name><surname>Roep</surname><given-names>BO</given-names></name><etal/></person-group><article-title>Strong association of MuSK antibody&#x02013;positive myasthenia gravis and HLA-DR14-DQ5</article-title><source>Neurology</source><year>2006</year><volume>66</volume><issue>11</issue><fpage>1772</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000218159.79769.5c</pub-id><pub-id pub-id-type="pmid">16769963</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Bartoccioni E, Scuderi F, Augugliaro et al (2009) HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72(2):195&#x02013;197</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alahgholi-Hajibehzad</surname><given-names>M</given-names></name><name><surname>Yilmaz</surname><given-names>V</given-names></name><name><surname>G&#x000fc;lsen-Parman</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of HLA-DRB*1, -DRB*16 and -DQB1*05 with MuSK-myasthenia gravis in patients from Turkey</article-title><source>Hum Immunol</source><year>2013</year><volume>74</volume><issue>12</issue><fpage>1633</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2013.08.271</pub-id><pub-id pub-id-type="pmid">23993985</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>P</given-names></name><name><surname>McKeon</surname><given-names>A</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Serologic diagnosis of NMO. A multicenter comparison of aquaporin-4-IgG assays</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>9</issue><fpage>665</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318248dec1</pub-id><pub-id pub-id-type="pmid">22302543</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez Cruz</surname><given-names>PM</given-names></name><name><surname>Huda</surname><given-names>S</given-names></name><name><surname>L&#x000f3;pez-Ruiz</surname><given-names>P</given-names></name><etal/></person-group><article-title>Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases</article-title><source>Exp Neurol</source><year>2015</year><volume>270</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2015.01.011</pub-id><pub-id pub-id-type="pmid">25783660</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devic</surname><given-names>P</given-names></name><name><surname>Petiot</surname><given-names>P</given-names></name><name><surname>Simonet</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antibodies to clustered acetylcholine receptor: expanding the phenotype</article-title><source>Eur J Neurol</source><year>2014</year><volume>21</volume><issue>1</issue><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1111/ene.12270</pub-id><pub-id pub-id-type="pmid">24112557</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsonis</surname><given-names>AI</given-names></name><name><surname>Zisimopoulou</surname><given-names>P</given-names></name><name><surname>Lazaridis</surname><given-names>K</given-names></name><etal/></person-group><article-title>MuSK autoantibodies in myasthenia gravis detected by cell based assay&#x02014;a multinational study</article-title><source>J Neuroimmunol</source><year>2015</year><volume>15</volume><issue>284</issue><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2015.04.015</pub-id><pub-id pub-id-type="pmid">26025053</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koneczny</surname><given-names>I</given-names></name><name><surname>Cossins</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name></person-group><article-title>The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis</article-title><source>J Anat</source><year>2014</year><volume>224</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/joa.12034</pub-id><pub-id pub-id-type="pmid">23458718</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Steigler</surname><given-names>AL</given-names></name><name><surname>Cameron</surname><given-names>TO</given-names></name><etal/></person-group><article-title>Lrp4 is a receptor for agrin and forms a complex with MuSK</article-title><source>Cell</source><year>2008</year><volume>135</volume><issue>2</issue><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.002</pub-id><pub-id pub-id-type="pmid">18848351</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>LRP4 serves as a coreceptor of agrin</article-title><source>Neuron</source><year>2008</year><volume>60</volume><issue>2</issue><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.10.006</pub-id><pub-id pub-id-type="pmid">18957220</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijbers</surname><given-names>MG</given-names></name><name><surname>Querol</surname><given-names>LA</given-names></name><name><surname>Niks</surname><given-names>EH</given-names></name><etal/></person-group><article-title>The expanding field of IgG4-mediated neurological autoimmune disorders</article-title><source>Eur J Neurol</source><year>2015</year><volume>22</volume><issue>8</issue><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1111/ene.12758</pub-id><pub-id pub-id-type="pmid">26032110</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoccioni</surname><given-names>E</given-names></name><name><surname>Scuderi</surname><given-names>F</given-names></name><name><surname>Minicuci</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Anti-MuSK antibodies: correlation with myasthenia gravis severity</article-title><source>Neurology</source><year>2006</year><volume>67</volume><issue>3</issue><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000228225.23349.5d</pub-id><pub-id pub-id-type="pmid">16894117</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niks</surname><given-names>EH</given-names></name><name><surname>van Leeuwen</surname><given-names>Y</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1</article-title><source>J Neuroimmunol</source><year>2008</year><volume>195</volume><issue>1&#x02013;2</issue><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.01.013</pub-id><pub-id pub-id-type="pmid">18384886</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klooster</surname><given-names>R</given-names></name><name><surname>Plomp</surname><given-names>JJ</given-names></name><name><surname>Huijbers</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice</article-title><source>Brain</source><year>2012</year><volume>135</volume><issue>Pt 4</issue><fpage>1081</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1093/brain/aws025</pub-id><pub-id pub-id-type="pmid">22396395</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viegas</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>L</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name><etal/></person-group><article-title>Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects</article-title><source>Exp Neurol</source><year>2012</year><volume>234</volume><issue>2</issue><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2012.01.025</pub-id><pub-id pub-id-type="pmid">22326541</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yumoto</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Burden</surname><given-names>S</given-names></name></person-group><article-title>Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses</article-title><source>Nature</source><year>2012</year><volume>489</volume><issue>7416</issue><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nature11348</pub-id><pub-id pub-id-type="pmid">22854782</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>O</given-names></name><name><surname>Hamuro</surname><given-names>J</given-names></name><name><surname>Motomura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autoantibodies to low-density lipoprotein receptor&#x02013;related protein 4 in Myasthenia Gravis</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><issue>2</issue><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1002/ana.22312</pub-id><pub-id pub-id-type="pmid">21387385</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pevzner</surname><given-names>A</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>K</given-names></name><etal/></person-group><article-title>Anti-LRP4 autoantibodies in AChR- and MuSK-antibody negative myasthenia gravis</article-title><source>J Neurol</source><year>2012</year><volume>259</volume><issue>3</issue><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1007/s00415-011-6194-7</pub-id><pub-id pub-id-type="pmid">21814823</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Tzartos</surname><given-names>JS</given-names></name><name><surname>Belimezi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><issue>4</issue><fpage>445</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.2393</pub-id><pub-id pub-id-type="pmid">22158716</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zisimopoulou</surname><given-names>P</given-names></name><name><surname>Evangelakou</surname><given-names>P</given-names></name><name><surname>Tzartos</surname><given-names>J</given-names></name><etal/></person-group><article-title>A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis</article-title><source>J Autoimmun</source><year>2014</year><volume>52</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2013.12.004</pub-id><pub-id pub-id-type="pmid">24373505</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Bealmear</surname><given-names>B</given-names></name><etal/></person-group><article-title>Autoantibodies to agrin in myasthenia gravis patients</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>e91816</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0091816</pub-id><pub-id pub-id-type="pmid">24632822</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasperi</surname><given-names>C</given-names></name><name><surname>Melms</surname><given-names>A</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name><etal/></person-group><article-title>Anti-agrin autoantibodies in myasthenia gravis</article-title><source>Neurology</source><year>2014</year><volume>82</volume><issue>22</issue><fpage>1976</fpage><lpage>1983</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000478</pub-id><pub-id pub-id-type="pmid">24793185</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartaud</surname><given-names>A</given-names></name><name><surname>Strochlic</surname><given-names>L</given-names></name><name><surname>Guerra</surname><given-names>M</given-names></name><etal/></person-group><article-title>MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction</article-title><source>J Cell Biol</source><year>2004</year><volume>165</volume><issue>4</issue><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1083/jcb.200307164</pub-id><pub-id pub-id-type="pmid">15159418</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katarzyna</surname><given-names>M</given-names></name><name><surname>Belaya</surname><given-names>K</given-names></name><name><surname>Leite</surname><given-names>M</given-names></name><etal/></person-group><article-title>Collagen Q&#x02014;a potential target for autoantibodies in myasthenia gravis</article-title><source>J Neurol Sci</source><year>2015</year><volume>348</volume><issue>1&#x02013;2</issue><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2014.12.015</pub-id><pub-id pub-id-type="pmid">25577314</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>MI</given-names></name><name><surname>Coutinho</surname><given-names>E</given-names></name><name><surname>Lana-Peixoto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Myasthenia gravis and neuromyelitis optica spectrum disorder. A multicenter study of 16 patients</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>20</issue><fpage>1601</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31825644ff</pub-id><pub-id pub-id-type="pmid">22551731</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotkine</surname><given-names>M</given-names></name><name><surname>Fellig</surname><given-names>Y</given-names></name><name><surname>Abramsky</surname><given-names>O</given-names></name></person-group><article-title>Occurrence of CNS demyelinating disease in patients with myasthenia gravis</article-title><source>Neurology</source><year>2006</year><volume>67</volume><issue>5</issue><fpage>881</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000234142.41728.a0</pub-id><pub-id pub-id-type="pmid">16966558</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isbister</surname><given-names>CM</given-names></name><name><surname>Mackenzie</surname><given-names>PJ</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name></person-group><article-title>Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia</article-title><source>Mult Scler</source><year>2003</year><volume>9</volume><issue>6</issue><fpage>550</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1191/1352458503ms964oa</pub-id><pub-id pub-id-type="pmid">14664466</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillane</surname><given-names>J</given-names></name><name><surname>Christofi</surname><given-names>G</given-names></name><name><surname>Sidle</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Myasthenia gravis and neuromyelitis optica: a causal link</article-title><source>Mult Scler Relat Disord</source><year>2013</year><volume>2</volume><issue>3</issue><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2013.01.003</pub-id><pub-id pub-id-type="pmid">25877729</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bever</surname><given-names>CT</given-names></name><name><surname>Aquino</surname><given-names>AV</given-names></name><name><surname>Penn</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Prognosis of ocular myasthenia</article-title><source>Ann Neurol</source><year>1983</year><volume>14</volume><issue>5</issue><fpage>516</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1002/ana.410140504</pub-id><pub-id pub-id-type="pmid">6651238</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Sommer N, Sigg B, Melms A et al (1997) Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156&#x02013;162</mixed-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupersmith</surname><given-names>MJ</given-names></name></person-group><article-title>Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up</article-title><source>J Neurol</source><year>2009</year><volume>256</volume><issue>8</issue><fpage>1314</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1007/s00415-009-5120-8</pub-id><pub-id pub-id-type="pmid">19377863</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Wong SH, Plant GT, Cornblath W (2015) Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol <bold>[Epub ahead of print]</bold></mixed-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mee</surname><given-names>J</given-names></name><name><surname>Paine</surname><given-names>M</given-names></name><name><surname>Byrne</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis</article-title><source>J Neuroophthalmol</source><year>2003</year><volume>23</volume><issue>4</issue><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1097/00041327-200312000-00002</pub-id><pub-id pub-id-type="pmid">14663303</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grob</surname><given-names>D</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Namba</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lifetime course of myasthenia gravis</article-title><source>Muscle Nerve</source><year>2008</year><volume>37</volume><issue>2</issue><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1002/mus.20950</pub-id><pub-id pub-id-type="pmid">18059039</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">Wong S, Petrie A, Plant G (2015) Ocular MG: towards a risk of generalisation (&#x02018;ROG&#x02019;) score. In: Association of British Neurologists (ABN) annual meeting, final programme and abstract book, 2015 May 20-2; Harrogate, UK: ABN; 2015 p 48</mixed-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Kaminski</surname><given-names>HJ</given-names></name></person-group><article-title>Treatment of myasthenia gravis</article-title><source>Curr Neurol Neurosci Rep</source><year>2011</year><volume>11</volume><issue>1</issue><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s11910-010-0151-1</pub-id><pub-id pub-id-type="pmid">20927659</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palace</surname><given-names>J</given-names></name><name><surname>Newsom-Davis</surname><given-names>J</given-names></name><name><surname>Lecky</surname><given-names>B</given-names></name><etal/></person-group><article-title>A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis</article-title><source>Neurology</source><year>1998</year><volume>50</volume><issue>6</issue><fpage>1778</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1212/WNL.50.6.1778</pub-id><pub-id pub-id-type="pmid">9633727</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckmann</surname><given-names>J</given-names></name><name><surname>Rawoot</surname><given-names>A</given-names></name><name><surname>Bateman</surname><given-names>K</given-names></name><etal/></person-group><article-title>A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis</article-title><source>BMC Neurol</source><year>2011</year><volume>5</volume><issue>11</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-11-97</pub-id><pub-id pub-id-type="pmid">21819556</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>McConville</surname><given-names>J</given-names></name><name><surname>Chaudhry</surname><given-names>V</given-names></name><etal/></person-group><article-title>Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients</article-title><source>Muscle Nerve</source><year>2004</year><volume>30</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/mus.20069</pub-id><pub-id pub-id-type="pmid">15221879</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddison</surname><given-names>P</given-names></name><name><surname>McConville</surname><given-names>J</given-names></name><name><surname>Farrugia</surname><given-names>ME</given-names></name><etal/></person-group><article-title>The use of rituximab in myasthenia gravis and Lambert Eaton myasthenic syndrome</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><issue>6</issue><fpage>671</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.197632</pub-id><pub-id pub-id-type="pmid">20392977</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000ed;az-Manera</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname><given-names>E</given-names></name><name><surname>Querol</surname><given-names>L</given-names></name><etal/></person-group><article-title>Long-lasting treatment effect of rituximab in MuSK myasthenia</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>3</issue><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182407982</pub-id><pub-id pub-id-type="pmid">22218276</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>R</given-names></name><name><surname>Damato</surname><given-names>V</given-names></name><name><surname>Aboini</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis</article-title><source>J Neurol</source><year>2015</year><volume>262</volume><issue>5</issue><fpage>1115</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1007/s00415-014-7532-3</pub-id><pub-id pub-id-type="pmid">25308632</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catzola</surname><given-names>V</given-names></name><name><surname>Battaglia</surname><given-names>A</given-names></name><name><surname>Buzzonetti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Changes in regulatory T-cells after rituximab in two patients with refractory myasthenia gravis</article-title><source>J Neurol</source><year>2013</year><volume>260</volume><issue>8</issue><fpage>2163</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1007/s00415-013-6987-y</pub-id><pub-id pub-id-type="pmid">23749295</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>JF</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name><name><surname>Cutter</surname><given-names>GR</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled phase II trial of eculizumab in patients with refractory generalized myasthenia gravis</article-title><source>Muscle Nerve</source><year>2013</year><volume>48</volume><issue>1</issue><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/mus.23839</pub-id><pub-id pub-id-type="pmid">23512355</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Clinical trials.gov. Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrials.gov identifier NCT01997229 [on-line]. Web-page last updated 2015 July 6. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01997229">https://clinicaltrials.gov/ct2/show/NCT01997229</ext-link>. Accessed 13 Aug 2015</mixed-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argov</surname><given-names>Z</given-names></name><name><surname>McKee</surname><given-names>D</given-names></name><name><surname>Agus</surname><given-names>S</given-names></name><etal/></person-group><article-title>Treatment of human myasthenia with oral antisense suppression of acetylcholinesterase</article-title><source>Neurology</source><year>2007</year><volume>69</volume><issue>7</issue><fpage>699</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000267884.39468.7a</pub-id><pub-id pub-id-type="pmid">17698793</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sussman</surname><given-names>J</given-names></name><name><surname>Argov</surname><given-names>Z</given-names></name><name><surname>Wirguin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Further developments with antisense treatment for myasthenia gravis</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1275</volume><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06825.x</pub-id><pub-id pub-id-type="pmid">23278572</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>DB</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name><name><surname>Dimachkie</surname><given-names>MM</given-names></name><etal/></person-group><article-title>A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><issue>2</issue><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0345-y</pub-id><pub-id pub-id-type="pmid">25742919</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>D</given-names></name><name><surname>Nouri</surname><given-names>MN</given-names></name><name><surname>Ng</surname><given-names>E</given-names></name><etal/></person-group><article-title>Comparison of IVIg and PLEX in patients with myasthenia gravis</article-title><source>Neurology</source><year>2011</year><volume>76</volume><issue>23</issue><fpage>2017</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31821e5505</pub-id><pub-id pub-id-type="pmid">21562253</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Barnett-Tapia</surname><given-names>C</given-names></name><name><surname>Barth</surname><given-names>D</given-names></name><etal/></person-group><article-title>IVIg and PLEX in the treatment of myasthenia gravis</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1275</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06767.x</pub-id><pub-id pub-id-type="pmid">23278570</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>A</given-names></name><name><surname>Pfister</surname><given-names>F</given-names></name><name><surname>Schalke</surname><given-names>B</given-names></name><etal/></person-group><article-title>Thymus pathology observed in the MGTX trial</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1275</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06799.x</pub-id><pub-id pub-id-type="pmid">23278583</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauriola</surname><given-names>L</given-names></name><name><surname>Ranelletti</surname><given-names>F</given-names></name><name><surname>Maggiano</surname><given-names>N</given-names></name><etal/></person-group><article-title>Thymus changes in anti-MuSK-positive and -negative myasthenia gravis</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>3</issue><fpage>536</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000150587.71497.B6</pub-id><pub-id pub-id-type="pmid">15699390</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>MI</given-names></name><name><surname>Str&#x000f6;bel</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG</article-title><source>Ann Neurol</source><year>2005</year><volume>57</volume><issue>3</issue><fpage>444</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1002/ana.20386</pub-id><pub-id pub-id-type="pmid">15732104</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Saka E, Topcuoglu MA, Akkaya B et al (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65(5):782&#x02013;783 <bold>(author reply 782&#x02013;3)</bold></mixed-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrager</surname><given-names>JB</given-names></name></person-group><article-title>Extended transcervical thymectomy: the ultimate minimally invasive approach</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>6</issue><fpage>S2128</fpage><lpage>S2134</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2010.02.099</pub-id><pub-id pub-id-type="pmid">20493996</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><mixed-citation publication-type="other">Freeman RK, Ascioti AJ, van Woerkom JM et al (2011) Long-term follow-up after robotic thymectomy for nonthymomatous myasthenia gravis. Ann Thorac Surg 92(3):1018&#x02013;1022 <bold>(discussion 1022&#x02013;3)</bold></mixed-citation></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">Marulli G, Schiavon M, Perissinotto E et al (2013) Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. J Thorac Cardiovasc Surg 145(3):730&#x02013;735 <bold>(discussion 735&#x02013;6)</bold></mixed-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillane</surname><given-names>J</given-names></name><name><surname>Hayward</surname><given-names>M</given-names></name><name><surname>Hirsch</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Thymectomy: role in the treatment of myasthenia gravis</article-title><source>J Neurol</source><year>2013</year><volume>260</volume><issue>7</issue><fpage>1798</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1007/s00415-013-6880-8</pub-id><pub-id pub-id-type="pmid">23508539</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keijzers</surname><given-names>M</given-names></name><name><surname>de Baets</surname><given-names>M</given-names></name><name><surname>Hochstenbag</surname><given-names>M</given-names></name><etal/></person-group><article-title>Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes</article-title><source>Eur J Cardiothorac Surg</source><year>2015</year><volume>48</volume><issue>1</issue><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezu352</pub-id><pub-id pub-id-type="pmid">25234092</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;ckert</surname><given-names>JC</given-names></name><name><surname>Swierzy</surname><given-names>M</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name></person-group><article-title>Comparison of robotic and nonrobotic thoracoscopic thymectomy: a cohort study</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><issue>3</issue><fpage>673</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2010.11.042</pub-id><pub-id pub-id-type="pmid">21335125</pub-id></element-citation></ref></ref-list></back></article>